UNSPSC 51142534: Mofegiline

This classification denotes a monoamine oxidase inhibitor with the molecular formula C11H13F2N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FMJ6D8Y1B, chemically known as benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (e)- but generally known as mofegiline, which bears US NIH Compound Identifier 6437850. European Medicines Agency schedules Mofegiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09034MIG.

UNSPSC 51142534 Mofegiline is a Commodity-tier code representing pharmaceutical products, though recent state and local solicitations tagged under this code show minimal alignment with mofegiline specifically and instead reflect broader pharmaceutical procurement — notably naloxone, generic multi-source drugs, and over-the-counter products distributed through established wholesaler networks and direct-to-manufacturer programs. State and local governments buying under this code include county health departments, state health agencies, and multistate cooperative purchasing alliances that supply pharmaceuticals to public health facilities, employee benefit programs, and community health initiatives. The work involves sourcing FDA-compliant pharmaceutical inventory, managing NDC-coded product specifications, arranging quarterly or ongoing deliveries, and complying with supply-chain security and Good Manufacturing Practice certifications.

Activity appears concentrated in Florida and the Upper Midwest multistate purchasing regions. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (with a note that the due date appears inconsistent with the posting date). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities including Oregon, with responses due March 26, 2026; this RFP requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and emphasizes price competitiveness (75 percent of evaluation weight) and cGMP and DSCSA compliance. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for self-insured employee health plans outside traditional PBM arrangements.